AllAnalyst Report
logoMorningstarNovember 24, 2020

Regeneron Pharmaceuticals, Inc.: Maintaining Our $500 Regeneron Fair Value Estimate Following REGN-COV2 Authorization

Symbols
REGN
Sector(s)
Healthcare
Rating
Premium
Current Price
$517.93
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE